Mutational analysis of gene families in human cancer.

The completion of the human genome project has marked a new beginning in biomedical sciences. Human cancer is a genetic disease and, accordingly, the field of oncology has been one of the first to be impacted by this historic revolution. Knowledge of the sequence and organization of the human genome facilitates the systematic analysis of the genetic alterations underlying the origin and evolution of tumors. Recent mutational analyses in colorectal and other cancers have focused on examination of gene families involved in signal transduction, such as kinases and phosphatases. This approach has been successful in identifying mutations in a variety of different genes, including the identification of PI3KCA as one of the most commonly mutated oncogenes in human cancer. Such genomic analyses have already demonstrated their utility in basic and clinical cancer research, and are expected to have an important impact on future diagnostic and therapeutic strategies.

[1]  Thomas Huber,et al.  Phosphoregulators: protein kinases and protein phosphatases of mouse. , 2003, Genome research.

[2]  J. Downward.  The ins and outs of signalling , 2001, Nature.

[3]  Joanna M. Sasin,et al.  Protein Tyrosine Phosphatases in the Human Genome , 2004, Cell.

[4]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[5]  Toshiyuki Fukada,et al.  A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[7]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Eddy.  Hidden Markov models. , 1996, Current opinion in structural biology.

[9]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[10]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[11]  M. Barbacid,et al.  T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes , 1982, Nature.

[12]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[13]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[14]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[15]  Giovanni Parmigiani,et al.  Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers , 2004, Science.

[16]  J. Fletcher,et al.  Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[18]  Douglas F. Easton,et al.  Association studies for finding cancer-susceptibility genetic variants , 2004, Nature Reviews Cancer.

[19]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[20]  Eugenio Santos,et al.  A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene , 1982, Nature.

[21]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[22]  B. Druker,et al.  Imatinib as a paradigm of targeted therapies. , 2004, Advances in cancer research.

[23]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[24]  Jun Luo,et al.  Looking Beyond Morphology: Cancer Gene Expression Profiling Using DNA Microarrays , 2003, Cancer investigation.

[25]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[26]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[27]  Giovanni Parmigiani,et al.  Prevalence of somatic alterations in the colorectal cancer cell genome , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[29]  Hiroyuki Konishi,et al.  The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.

[30]  B. Neel,et al.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. , 2003, Trends in biochemical sciences.

[31]  M. Sulis,et al.  PTEN: from pathology to biology. , 2003, Trends in cell biology.

[32]  G. Parmigiani,et al.  Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers , 2003, Science.

[33]  B. Neel,et al.  Combinatorial control of the specificity of protein tyrosine phosphatases. , 2001, Current opinion in cell biology.

[34]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[35]  G. Martin,et al.  The road to Src , 2004, Oncogene.

[36]  S. Hanash,et al.  Integrated global profiling of cancer , 2004, Nature Reviews Cancer.

[37]  T. Hunter,et al.  The role of tyrosine phosphorylation in cell growth and disease. , 1998, Harvey lectures.

[38]  W. Cavenee,et al.  Identification and validation of tumor suppressor genes. , 1999, Molecular cell biology research communications : MCBRC.

[39]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[40]  R. McLendon,et al.  Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas , 2004, Cancer Research.

[41]  Cori Bargmann,et al.  Mechanism of activation of a human oncogene , 1982, Nature.

[42]  H T Lynch,et al.  Hereditary colorectal cancer. , 1991, Seminars in oncology.

[43]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[44]  R Simon,et al.  Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data , 2003, British Journal of Cancer.